subscribe
 

Researchers reveal malaria's deadly grip

International researchers have identified how malaria parasites growing inside red blood cells stick to the sides of blood vessels in severe...

Curie-Cancer and Biolog-id sign partnership agreement

Within the partnership, Curie-Cancer and Biolog-id will develop a pilot system of RFID tags suitable for use in tracking cancer chemotherapy preparations

Sub-Visible Particles: impact on therapeutic proteins

SP Scientific has announced a new LyoLearn webinar, due to run on 27th June 2013, entitled 'Sub-visible Particles: Impacts on Aggregation...

Arthritis Research UK - Promoting effective and efficient reporting

In a world increasingly focused on accountability, over 30 leading research funding organisations including Arthritis Research UK have joined forces to use a new research outcomes reporting system called Researchfish.

Patients at risk of heart disease set to benefit from clinical trial

Patients suffering from high blood pressure - the single most important risk for death worldwide - could be helped by a UK-wide clinical trial aimed at improving treatments.

Auxogyn selected to present at European BioEquity Conference in Stockholm

BioEquity is the top European event for life science investors showcasing companies on the forefront of innovation.

Transgene announces its invesment in ElsaLys Biotech

The Start-up company will develop therapeutic antibodies against novel targets in the fields of cancer and inflammation.

Drug candidates hold promise for HIV drugs market

Patients to benefit from potential for improved efficacy in less commonly used types of antiretroviral therapies and one-pill-daily combination drugs

Development and licensing deals speed up new drug development

Technology licensing tie-ups and more targeted discovery solutions are driving new drug developments

Queen’s scientists develop ‘magic bullet’ nanomedicine for Acute Lung Injury

Researchers at Queen’s University Belfast have devised a ‘magic bullet’ nanomedicine which could become the first effective treatment for Acute Lung Injury or ALI, a condition affecting 20 per cent of all patients in intensive care.

Novartis drug Ilaris® approved by FDA

Novartis announced that the US Food and Drug Administration (FDA) has approved Ilaris® (canakinumab) for the treatment of active systemic juvenile idiopathic arthritis (SJIA) in patients aged 2 years and older.

World Lupus Day

Oxford Gene Technology marks World Lupus Day with announcement of novel biomarker panel to support earlier SLE diagnosis

European multidisciplinary conference in thoracic oncology

New data presented at EMCTO showed that first-line therapy with gefitinib (IRESSATM) in Caucasian patients with EGFR mutation-positive advanced NSCLC resulted in an ORR of 70% (95% CI 61-78)

New nanoparticles research

A Wayne State University researcher has successfully tested a technique that can lead to more effective use of nanoparticles as a drug delivery system.

Study finds nearly 5 million asthmatics worldwide could benefit from antifungal therapy

An estimated 4,837,000 asthmatics with allergic bronchopulmonary aspergillosis (ABPA) could benefit substantially from antifungal treatment, say researchers from the University of Toronto and Manchester University.

Study confirms Everolimus can overcome Trastuzumab resistance in IN HER-2 positive early breast cancer

A study that aimed to understand how the cancer drug everolimus helps overcome the resistance breast cancers can develop to trastuzumab has...

NanoKTN supports regenerative medicine development

UK regenerative medicine platform (UKRMP) safety hub announced

Bayer to broaden alliance with German Cancer Research Centre

Bayer HealthCare and the German Cancer Research Centre will extend their successful strategic research alliance in search of novel cancer therapeutics.

World Drug Safety Congress

Sciformix Corporation has announced its premium sponsorship of the 5th annual World Drug Safety Congress, taking place from April 24 - 25, 2013 in Boston.

Oncodesign in partnership with Sanofi

Oncodesign signs a partnership agreement and an option for exclusive licensing with Sanofi in the area of tissue protection and repair.

Pages

Newsbrief

FREE NEWSBRIEF SUBSCRIPTION

To receive the Scientist Live weekly email NewsBrief please enter your details below

Twitter Icon © Setform Limited
subscribe